[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypertension\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypertension":26},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,518,0,25,[9,44,75,123,152,174,201,235,257,287,314,341,360,387,409,432,458,487,518,540,568,595,619,650,679],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100628380","the-impact-of-low-sodium-salt-substitute-use-on-serum-potassium-levels-among-patients-with-hypertension-100628380",false,"NCT07460882","The Impact of Low Sodium Salt Substitute Use on Serum Potassium Levels Among Patients With Hypertension","Inclusion Criteria:\n\n* Adults ≥18 years with clinically diagnosed hypertension treated with medication \\[on a stable dose at least for 2 months\\]\n* Have a phone for contact\n\nExclusion Criteria:\n\n* Those with baseline K ≥5.0 or K \\\u003C3.0 mmol\u002FL\n* Advanced kidney disease (eGFR \\\u003C45 ml\u002Fmin\u002F1.73m2).\n* Those on potassium sparing diuretics (e.g., spironolactone)\n* Other medical conditions determined by physicians (e.g., heart failure treated with medication; life expectancy less than 12 months)\n* Dine out for dinner more than 3 times a week","ALL","18 Years",{"count":19,"type":20},607,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this pre-post study is to assess the risk of hyperkalemia in adults with hypertension on medication in Bangladesh. The main questions it aims to answer are:\n\nIs the risk of hyperkalemia after the initiation of Low Sodium Salt Substitute (LSSS) in people on antihypertensive medication (especially RASi) large enough to be concerned about its broad use in this population?\n\nDoes initiation of LSSS correct hypokalemia in people on antihypertensive medication (especially RASi) with low serum potassium levels?\n\nParticipants will be asked to reduce overall salt intake and to use LSSS on every occasion where regular salt would normally be used, including as cooking salt.",[26],"Hypertension",[26,28,29,30],"Low sodium salt substitute","Cardiovascular disease","RASi","RECRUITING","2026-08-20",{"date":34,"type":35},"2026-08-21","ACTUAL",{"date":37,"type":35},"2026-08-08",{"date":39,"type":20},"2027-09-30",{"name":41,"class":42},"Johns Hopkins University","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":62,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":68,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":43},"100616841","digital-care-for-holistic-health-in-older-adults-with-diabetes-and-multimorbidity-100616841","NCT07310849","Digital Care for Holistic Health in Older Adults With Diabetes and Multimorbidity","Digital Care Community Common Good Program Enhances Holistic Health Management for Middle Aged and Older Adults With Diabetes Mellitus and Multiple Chronic Conditions","Inclusion Criteria:\n\n* Age and Consent: Individuals aged 50 years or older who are willing to provide written informed consent.\n* Language and Literacy: Participants must be literate and able to communicate in Mandarin or Taiwanese.\n* Medical Diagnosis: Participants must have a physician-confirmed diagnosis of type 2 diabetes mellitus (T2DM) and at least one comorbid chronic disease (e.g., hypertension, hyperlipidemia, chronic kidney disease, or heart disease).\n* Technology Use: Participants must own a smartphone and be willing to use the LINE messaging app and web-based health education links.\n* Residence: Participants must reside within one of the four participating communities and have no plans to move away during the study intervention period.\n\nExclusion Criteria:\n\n* Those with severe diabetes-related complications, such as renal failure, cerebrovascular disease, diabetic foot, or retinopathy.\n* Individuals with psychiatric disorders, undergoing active cancer treatment, or those unable to perform independent self-care (e.g., due to visual impairment or mobility limitations).\n* Individuals without diabetes but with other chronic diseases.\n* Individuals residing in long-term care institutions.\n* Individuals who are simultaneously participating in other intervention programs.","50 Years",{"count":53,"type":20},169,[23],"The purpose of this study was to explore the effectiveness of the \"Digital Care Community Common Good\" program in improving disease control indicators, self-management abilities, depression, and quality of life among patients with comorbidities and type 2 diabetes. The study was designed as a two-year experimental study, with a specific area in New Taipei City selected as the research site. In the first year, the main tasks include establishing an integrated intervention team composed of primary healthcare providers and community resources, expanding the functionalities of the mHealth platform, developing digital educational materials for diabetes comorbidities care, and recruiting and training 6 to 8 community care volunteers. Additionally, 169 eligible participants with type 2 diabetes and comorbidities will be recruited from four communities, completing baseline assessments and randomization into groups. In the second year, a 6-month intervention and effectiveness evaluation of the \" Digital Care Community Common Good \" program will be implemented. The intervention includes online and in-person educational sessions, telephone care, use of the mHealth platform (featuring educational, data monitoring, contextual learning, interactive, and reminders), as well as home visits, case discussions, and individualized care plans for high-risk cases. Disease control indicators, selfmanagement abilities, depression, and quality of life will be tracked immediately post-intervention, at 3 month, and at 6 month to assess outcomes and changes over time. This study expects to enhance health management for diabetes patients with comorbidities through digital care and interdisciplinary collaboration, offering evidence-based insights and recommendations for policy implementation in the integration of community and primary healthcare models.",[57,26,58,59,60,61],"Type2Diabetes","Dyslipidemia","CKD","Cardio Vascular Disease","Gout Arthritis",[63,64,65,66,67],"community care","diabetes mellitus","multimorbidity","quality of life","self-management",{"date":34,"type":35},{"date":70,"type":35},"2026-05-12",{"date":72,"type":20},"2027-07-01",{"name":74,"class":42},"Chang Gung University of Science and Technology",{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":16,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":115,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":122},"100383878","pharmacokinetics-pharmacodynamics-and-safety-profile-of-understudied-drugs-administered-to-children-per-standard-of-care-pops-100383878","NCT04278404","Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs","POPS or POP02","Inclusion Criteria:\n\n1. Participant is \\\u003C 21 years of age\n2. Parent\u002F Legal Guardian\u002F Adult Participant can understand the consent process and is willing to provide informed consent\u002FHIPAA:\n3. (a) Participant is receiving one or more of the study drugs of interest at the time of enrollment or (b) Participant is NOT receiving one or more of the study drugs of interest but is SARS-COV-2 positive within 60 days prior to enrollment\n\nExclusion Criteria:\n\n1. Participant has a known pregnancy\n\n   Below exclusion criteria apply only to:\n\n   Participants receiving one or more of the study drugs of interest at the time of enrollment, DOI administration or PK sampling: (Refer to DOI specific appendices for details on enrollment cohort specifications and additional eligibility criteria)\n2. Has had intermittent dialysis within previous 24 hours\n3. Has had a kidney transplant within previous 30 days\n4. Has had a liver transplant within previous 1 year\n5. Has had a stem cell transplant within previous 1 year\n6. Has had therapeutic hypothermia within previous 24 hours\n7. Has had plasmapheresis within the previous 24 hours\n8. Has a Ventricular Assist Device\n9. Has any condition which would make the participant, in the opinion of the investigator, unsuitable for the study",true,"0 Years","20 Years",{"count":87,"type":20},5000,"OBSERVATIONAL","The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.",[91,92,93,26,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114],"Coronavirus Infection (COVID-19)","Pulmonary Arterial Hypertension","Urinary Tract Infections in Children","Pain","Hyperphosphatemia","Primary Hyperaldosteronism","Edema","Hypokalemia","Heart Failure","Hemophilia","Menorrhagia","Insomnia","Pneumonia","Skin Infection","Arrythmia","Asthma in Children","Bronchopulmonary Dysplasia","Adrenal Insufficiency","Fibrinolysis; Hemorrhage","Attention Deficit Hyperactivity Disorder","Multisystem Inflammatory Syndrome in Children (MIS-C)","Kawasaki Disease","Coagulation Disorder","Down Syndrome",{"date":34,"type":35},{"date":117,"type":35},"2020-03-05",{"date":119,"type":20},"2026-12",{"name":121,"class":42},"Duke University",52,{"id":124,"slug":125,"hasResults":12,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":21,"phases":134,"briefSummary":136,"conditions":137,"keywords":139,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":43},"100599382","phase-3-renal-artery-denervation-assessment-without-antihypertensive-medication-regimen-radar-100599382","NCT07083765","Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)","A Prospective Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation Using the Dehydrated Alcohol Injection, USP Administered With the Peregrine System™ Infusion Catheter in Subjects With Hypertension, in the Absence of Antihypertensive Medications","RADAR","Inclusion Criteria:\n\n1. Has 2 office blood pressure measurements with a mean office systolic blood pressure (SBP) of ≥150 mmHg and ≤180 mmHg, AND a mean office diastolic blood pressure (DBP) of ≥90 mmHg.\n2. Documented history of uncontrolled hypertension and is currently taking 0, 1, or 2 antihypertensive medications.\n3. Is willing to discontinue any current antihypertensive medications for at least 13 weeks (5-week pre-procedure and 8-week post-procedure).\n4. Has a mean 24-hour ambulatory SBP of ≥140 mmHg and ≤170 mmHg with required valid readings.\n\nExclusion Criteria:\n\n1. Has renal artery anatomy abnormalities.\n2. Has previously undergone renal denervation.\n3. Has an estimated glomerular filtration rate (eGFR) of ≤45 mL\u002Fmin\u002F1.73 m2, based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation; or is on chronic renal replacement therapy.\n4. Has documented untreated sleep apnea.\n5. Has any of the following conditions: severe cardiac valve stenosis, heart failure (New York Heart Association \\[NYHA\\] Class III or IV), chronic atrial fibrillation (defined as at least one documented episode in the 12 months before study entry), and known primary pulmonary hypertension (\\>60 mmHg pulmonary artery or right ventricular systolic pressure).\n6. Is pregnant or lactating at the time of enrollment or planning to become pregnant during the trial time period (female subjects only).\n7. Is being treated chronically (e.g. daily use) with NSAIDs, immunosuppressive medications, or immunosuppressive doses of steroids. Aspirin therapy and nasal pulmonary inhalants are allowed.\n8. Has a history of myocardial infarction, unstable angina pectoris, or stroke\u002FTIA within 6 months prior to the planned procedure.","80 Years",{"count":133,"type":20},202,[135],"PHASE3","To obtain an assessment of the efficacy and safety of renal denervation by dehydrated alcohol injection, USP administered via the Peregrine System™ Infusion Catheter in hypertensive subjects in the absence of antihypertensive medications.",[26,138],"Hypertension,Essential",[140,141],"Renal denervation","Neurolysis","NOT_YET_RECRUITING","2026-08-19",{"date":32,"type":35},{"date":146,"type":20},"2026-10",{"date":148,"type":20},"2029-02",{"name":150,"class":151},"Ablative Solutions, Inc.","INDUSTRY",{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":21,"phases":161,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":166,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":173},"100597898","phase-3-easi-protkt---a-study-to-test-vicadrostat-bi-690517-taken-together-with-empagliflozin-in-people-with-type-2-diabetes-high-blood-pressure-and-cardiovascular-disease-100597898","NCT07064473","EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease","EASi-PROTKT™ - A Phase III Double-blind, Randomised, Parallel-group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrostat (BI 690517) and Empagliflozin Compared With Placebo and Empagliflozin in Participants With Type 2 Diabetes, Hypertension and Established Cardiovascular Disease","Inclusion Criteria :\n\n* At least 18 years old at time of consent\n* Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial\n* Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per ICH M3 (R2).\n* Participants with medical history of hypertension and on active pharmacological treatment\n* Participants with medical history of type 2 diabetes mellitus (T2DM) and on active pharmacological treatment\n* Established cardiovascular (CV) disease and on active pharmacological treatment\n* At least one additional risk factor for developing heart failure (HF)\n\nExclusion Criteria:\n\n* History of HF or hospitalization for HF or treatment of HF\n* Atrial fibrillation or Atrial flutter with a resting heart rate \\>110 beats per minute (bpm) documented by echocardiogram (ECG) at Visit 1 (screening)\n* Advanced untreated conduction disease or untreated clinically relevant ventricular arrhythmia at Visit 1 (screening)\n* Treatment with an Mineralocorticoid receptor antagonist (MRA)\n* Treatment with amiloride or other potassium-sparing diuretic\n* Receiving the following treatments at Visit 1 (screening) or requiring such treatment before Visit 2 (randomisation), or planned during the trial:\n\n  * A direct renin inhibitor (e.g. aliskiren)\n  * More than one Angiotensin-converting enzyme inhibitor (ACEi) and\u002For Angiotensin receptor blocker (ARB) (including Angiotensin receptor-neprilysin inhibitor (ARNi)) used simultaneously\n  * Other aldosterone synthase inhibitors (e.g. baxdrostat)\n  * Systemic mineralocorticoid replacement therapy (e.g. fludrocortisone) Further exclusion criteria apply.",{"count":160,"type":20},11800,[135],"This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. The purpose of this study is to find out if a medicine called vicadrostat, when taken with empagliflozin, helps reduce cardiovascular risk in people with these conditions. The study will compare this combination to a placebo version of vicadrostat with empagliflozin.\n\nParticipants are put into 2 groups randomly, which means by chance. One group takes vicadrostat and empagliflozin tablets, and the other group takes placebo tablets with empagliflozin. Placebo tablets look like vicadrostat tablets but do not contain any medicine.\n\nParticipants take a tablet once per day for 2 and a half years and up to 4 years and 3 months. All participants also continue their medication for type 2 diabetes, high blood pressure, and cardiovascular disease. Participants have an equal chance of receiving the study medicine or placebo.\n\nParticipants are in the study for up to 4 years and 3 months. During this time, they visit the study site regularly. During these visits, doctors collect information about participants' health and take blood samples. The doctors document when participants experience cardiovascular events. The doctors also regularly check participants' health and take note of any unwanted effects.",[164,26,165],"Diabetes Mellitus, Type 2","Cardiovascular Diseases",{"date":32,"type":35},{"date":168,"type":35},"2025-07-22",{"date":170,"type":20},"2029-12-21",{"name":172,"class":151},"Boehringer Ingelheim",1147,{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":12,"sex":16,"minAge":181,"maxAge":182,"enrollmentInfo":183,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":185,"conditions":186,"keywords":188,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":193,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":43},"100575896","childhood-onset-essential-hypertension-natural-history-study-100575896","NCT06778239","Childhood-Onset Essential Hypertension Natural History Study","Natural History Study to Determine Childhood-Onset Essential Hypertension Etiology","* INCLUSION CRITERIA:\n\nTo be eligible to participate in this study, an affected individual must meet one of the following criteria:\n\n* Age 2-12 years at time of enrollment with a BP of at least \\>95th percentile or 120\u002F80 mm Hg verified via medical record review and a willingness to provide biological samples, undergo physical exam, provide information related to family and medical history, and undergo imaging\u002Fbody measurements (e.g., renal ultrasound)\n* Age 13-17 years at time of enrollment with a BP of at least 130\u002F80 mm Hg verified via medical record review and a willingness to provide biological samples, undergo physical exam, provide information related to family and medical history, and undergo imaging\u002Fbody measurements (e.g., renal ultrasound)\n* Age 18 years or more at time of enrollment with a medical history of meeting the criteria outlined in affected individual inclusion criteria 1 or 2, depending on age at diagnosis (verified via medical record review) and a willingness to provide biological samples, undergo physical exam, and provide information related to family and medical history\n\nTo be eligible to participate in this study, an unaffected individual must meet all of the following criteria:\n\n* First-degree relative to a proband (first identified affected family member) in the study\n* Willingness to provide biological samples, undergo physical exam, and provide information related to family and medical history\n\nTo be eligible to participate in this study, an individual with a candidate variant (regardless of known COEH status) must meet all of the following criteria:\n\n* History of clinical and\u002For research genomic interrogation\n* Positive genomic interrogation test result for candidate variant identified in earlier stages of study or in prior studies performed by study team\n* Willingness to provide information related to family and medical history, provide access to relevant medical records, undergo physical exam, and undergo imaging\u002Fbody measurements (if 2-17 years of age and evidence of COEH exists)\n\nEXCLUSION CRITERIA:\n\nAn affected individual who meets any of the following criteria will be excluded from participation in this study:\n\n* BMI \\>95th percentile\n* Evidence that hypertension is secondary to a known condition (e.g., chronic kidney disease, aortopathy, sleep apnea, etc.)\n* Impaired decision-making capability, with or without a legally-authorized representative\n\nAn unaffected individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Prior or current diagnosis of COEH\n* Second-degree or greater relationship to proband\n* Impaired decision-making capability, with or without a legally-authorized representative\n\nAn individual with a candidate variant (regardless of known COEH status) who meets any of the following criteria will be excluded from participation in this study:\n\n* No prior genomic interrogation findings available for the study team to review to confirm positive candidate variant status\n* Impaired decision-making capability, with or without a legally-authorized representative","2 Years","99 Years",{"count":184,"type":20},2300,"Background:\n\nChildhood-onset essential hypertension (COEH) is high blood pressure that develops in children and teens. High blood pressure is a major risk factor for heart disease. COEH is more likely to be caused by changes in genes rather than by factors like stress or diet. Researchers want to learn more about how changes in genes relate to COEH. They hope to use that information to develop better treatments for children with high blood pressure.\n\nObjective:\n\nThis natural history study will look for genes and gene changes that may lead to COEH.\n\nEligibility:\n\nPeople aged 2 years and older with COEH or who had COEH when they were children. Healthy relatives of those with COEH are also needed.\n\nDesign:\n\nParticipants will have one clinic visit per year for up to 10 years. All participants will have a physical exam. They will provide samples of blood and urine. At their first visit, they will have a swab (like a Q-tip) rubbed between their gums and cheeks. They may agree to having a skin biopsy; a piece of skin about the size of a pencil eraser will be removed.\n\nAffected participants aged 2 to 17 years old will have additional tests:\n\n* They will have sensors placed on their skin to look at their blood vessels and see how blood is moving in their bodies.\n* They will lie or stand while a machine measures the amount of fat and muscle in their bodies.\n* They will have an ultrasound; a wand will be rubbed against their skin to take pictures of their kidneys.\n\nOther things are optional for all participants:\n\n* They may have photographs taken of their bodies.\n* They may have tests of their heart function.\n* They may have different types of imaging scans....",[26,187],"Essential Hypertension",[189,190,191,192,26],"Blood Pressure","Pediatric","childhood hypertension","ESSENTIAL HYPERTENSION",{"date":32,"type":35},{"date":195,"type":35},"2025-05-30",{"date":197,"type":20},"2034-12-09",{"name":199,"class":200},"National Human Genome Research Institute (NHGRI)","NIH",{"id":202,"slug":203,"hasResults":12,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":12,"sex":16,"minAge":209,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":21,"phases":212,"briefSummary":213,"conditions":214,"keywords":218,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":43},"100652941","ceeec-ii-a-12-week-physical-and-cognitive-enrichment-extension-study-in-older-stroke-survivors-with-multimorbidity-100652941","NCT07778771","CEEEC-II: A 12-Week Physical and Cognitive Enrichment Extension Study in Older Stroke Survivors With Multimorbidity","A 12-Week, Multicenter, Open-Label, 2×2 Factorial, Cluster-Assigned Extension Study of Upgraded Physical and AI-Enabled Large-Screen Cognitive Enrichment for Older Stroke Survivors With Multimorbidity in Kunshan, China","CEEEC-II","Inclusion Criteria:\n\n* Completed the endpoint assessment of the preceding CEEEC Phase I trial (NCT06975501) and remains under management at a participating community health service station in Kunshan.\n* Age 60 years or older.\n* Hospital-confirmed ischemic or hemorrhagic stroke in a stable stage, with no new or worsening neurological deficit within the previous 3 months.\n* Registered hypertension and\u002For type 2 diabetes mellitus; other comorbid conditions are permitted.\n* Willing and able to participate in the 12-week community-based extension program and complete baseline and endpoint assessments.\n* Able to travel to the community site independently or with a cane or walker; not dependent on a wheelchair for attendance.\n* Short Physical Performance Battery total score \\>=3, or able to maintain a supported side-by-side standing position for 10 seconds when the total score is \\\u003C3.\n* Able to communicate in Mandarin Chinese or the Kunshan dialect and able to recognize Arabic numerals.\n* Corrected vision sufficient to identify large characters at approximately 40 cm and at least one upper limb able to complete touchscreen selection.\n* Resides in the participating community and has no plan to move away during the study period.\n* Provides written informed consent specifically for CEEEC-II.\n\nExclusion Criteria:\n\n* Life-threatening disease or another condition associated with an expected survival of less than 6 months.\n* A new stroke, transient ischemic attack, acute coronary event, or hospitalization for decompensated heart failure within the previous 3 months.\n* Uncontrolled resting blood pressure (systolic \\>=180 mmHg or diastolic \\>=110 mmHg after repeated measurement) until clinically reassessed and controlled.\n* Extreme glycemic instability, including fasting blood glucose \\>16.7 mmol\u002FL or severe hypoglycemia requiring assistance within the previous month, until clinically reassessed.\n* An absolute contraindication to unsupervised community exercise or another medical condition judged by the study clinician to make participation unsafe.\n* Unable to walk to the community site even with a cane or walker, or dependent on a wheelchair for attendance.\n* A severe musculoskeletal, neurological, visual, hearing, cognitive, psychiatric, or communication impairment that prevents safe participation or valid completion of study procedures.\n* Unable to recognize Arabic numerals or unable to complete touchscreen selection with either upper limb.\n* Current participation in another structured physical, cognitive, or nutrition intervention study that may contaminate the assigned intervention.\n* Any other reason documented by the study clinician as making the individual unsuitable for participation.","60 Years",{"count":211,"type":20},365,[23],"CEEEC-II is a 12-week, community-based, prospective extension study conducted in 32 community health service stations in Kunshan, China. It will invite older stroke survivors with hypertension and\u002For type 2 diabetes who participated in the preceding CEEEC Phase I trial (NCT06975501) to provide new informed consent and complete Phase II eligibility and baseline assessments. Participants will remain in the physical enrichment, cognitive enrichment, combined enrichment, or usual-care arm assigned to their community cluster in Phase I; no new randomization will occur in CEEEC-II. The upgraded program includes eight physician-led Vitality Camp sessions and four volunteer-led reinforcement activities. The physical component integrates aerobic, resistance, balance, flexibility, Baduanjin, and nutrition education. The cognitive component integrates health education with age-adapted games delivered through an AI-enabled interactive large screen. The primary objective is to evaluate the marginal effect of the cognitive enrichment factor on intrinsic capacity at 12 weeks.",[215,26,216,217],"Stroke","Type 2 Diabetes Mellitus (T2DM)","Multimorbidity",[219,220,221,222,223,224,225,226],"Intrinsic Capacity","Older Adults","Community Health Services","Environmental Enrichment","Cognitive Training","Physical Exercise","Multicomponent Intervention","Cluster-Assigned Extension Study","2026-08-18",{"date":34,"type":35},{"date":230,"type":20},"2026-08-31",{"date":232,"type":20},"2027-01-03",{"name":234,"class":42},"Duke Kunshan University",{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":242,"targetDuration":181,"studyType":88,"phases":4,"briefSummary":244,"conditions":245,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":250,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":43},"100652322","cardiovascular-kidney-metabolic-ckm-guided-therapy-for-patients-after-acute-coronary-syndrome-100652322","NCT07773272","Cardiovascular-kidney-metabolic (CKM)-Guided Therapy for Patients After Acute Coronary Syndrome","SLIM-3","Inclusion Criteria:\n\n* Age \\> 18 years\n* Hospitalised with acute coronary syndrome\n* Underwent percutaneous coronary intervention\n\nExclusion Criteria:\n\n* Acute coronary syndrome secondary to other diseases\n* Life expectancy \\\u003C 1 year based on the clinician's expertise",{"count":243,"type":20},1215,"Patients with a history of myocardial infarction are at significantly increased risk of recurrent cardiovascular events. Despite established clinical guidelines, secondary preventive care is often initiated too late, inadequate in intensity or incomplete in application. As a result, important opportunities to prevent serious outcomes are missed.\n\nThe aim of this project is to investigate whether rapid, guideline-based treatment following myocardial infarction leads to improved patient outcomes. The study protocol is based on current clinical guidelines and targets key domains including diabetes, hypertension, and hypercholesterolemia. Outcomes of patients treated according to the study protocol will be compared to those receiving standard care. Primary endpoints include major adverse cardiac- and cerebrovascular events within a 24-month follow-up period.\n\nThe investigators hypothesize that rapid, guideline-based intervention will result in improved risk factor management, leading to a reduction in cardiovascular events and mortality. For patients, this may translate into improved health, quality of life and life expectancy. This project aims to deliver a practical protocol for effective secondary prevention in clinical practice, which is expected to reduce healthcare utilization in the long term. With this initiative, the investigators seek to take a significant step toward improving post-myocardial infarction care and contributing to sustainable cardiovascular healthcare.",[246,247,26,248,249],"Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)","Hypercholerolemia","Diabete Mellitus","Cardiovascular Risk Management",{"date":143,"type":35},{"date":252,"type":35},"2026-03-16",{"date":254,"type":20},"2029-03-31",{"name":256,"class":42},"Zuyderland Medisch Centrum",{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":263,"eligibilityCriteria":264,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":21,"phases":267,"briefSummary":268,"conditions":269,"keywords":272,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":279,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":286},"100606865","phase-3-zilebesiran-in-patients-with-hypertension-not-adequately-controlled-and-with-either-established-cardiovascular-disease-or-high-risk-for-cardiovascular-disease-100606865","NCT07181109","Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease","ZENITH: A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease","ZENITH","Inclusion Criteria:\n\n* Is 18 years or older for patients with established cardiovascular disease (CVD)\n* Is 55 years or older for patients with high risk for CVD\n* Has established CVD (defined as coronary, cerebrovascular, or peripheral artery disease) or high risk for CVD\n* Has treated hypertension on stable therapy with at least 2 standard of care antihypertensive medications, one of which must be a thiazide, thiazide-like, or loop diuretic\n\nExclusion Criteria:\n\n* Has known history of secondary hypertension\n* Has symptomatic orthostatic hypotension\n* Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>3×upper limit of normal (ULN)\n* Has total serum bilirubin \\>1.5×ULN\n* Has international normalized ratio (INR) \\>1.5\n* Has serum potassium \\>4.8 mEq\u002FL\n* Has estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73m\\^2",{"count":266,"type":20},11000,[135],"The purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) events. This is an event-driven study that will continue until the targeted number of positively adjudicated primary endpoint clinical outcome events (COEs) have been reached.",[270,26,271],"High Risk Cardiovascular Disease","High Cardiovascular Risk",[273,274,275,276,29,277,278],"High blood pressure","siRNA","Angiotensinogen","AGT","Uncontrolled hypertension","RNAi",{"date":143,"type":35},{"date":281,"type":35},"2025-09-22",{"date":283,"type":20},"2030-09-30",{"name":285,"class":151},"Alnylam Pharmaceuticals",1105,{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":291,"acronym":292,"eligibilityCriteria":293,"healthyVolunteers":83,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":21,"phases":296,"briefSummary":297,"conditions":298,"keywords":301,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":308,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":312,"locationsCount":43},"100584635","groceries-for-residents-of-southeastern-usa-to-stop-hypertension-100584635","NCT06891911","Groceries for Residents of Southeastern USA to Stop Hypertension","GoFreshSE","Inclusion Criteria:\n\n1. Resting systolic blood pressure of 120 to \\\u003C160 mm Hg and diastolic blood pressure \\\u003C110 mm Hg\n2. Resident of Florida, Georgia, and Tennessee\n3. Able to receive home-delivered groceries or pick them up at a convenient location and willing to eat only the groceries provided over a 4-week period\n4. Have access to refrigeration, cooking appliances, and Wi-Fi\u002Fcellular service\n5. Have access to mobile device or computer to be able to conduct grocery orders via video conference and send\u002Freceive text messages\n6. Willing and able to complete required measurement procedures\n7. Able to provide consent for the study\n8. Has access to a primary care team, urgent care center, or emergency room the study team can refer to for follow up care if warranted during the study\n\nExclusion Criteria:\n\nA. Laboratory Exclusions:\n\n1. Serum potassium ≥5.4 mmol\u002FL or \\\u003C3.5 mmol\u002FL\n2. Estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin per 1.73 m\\^2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation\n3. Hemoglobin A1c ≥6.5%\n\nB. Medication Exclusions:\n\nUnstable doses (i.e. a change in the 6 months prior to screening or randomization or planning to start within study period) of the following:\n\n1. GLP-1 and dual GLP-1\u002FGIP receptor agonists\n2. Anti-hypertension medications\n3. Sodium-glucose co-transporter 2 (SGLT2) inhibitors\n4. Glucose lowering medications\n\nUse of any of the following medications:\n\n1. Potassium supplement, except if part of a multivitamin\n2. Warfarin (Coumadin)\n3. Chronic oral corticosteroid (intermittent use is okay)\n4. Weight loss medications (non-GLP-1 receptor agonists)\n5. Sulfonylurea or any insulin use\n\nAny medication not compatible with participation as determined by the investigators\n\nC. Physical Exclusions:\n\n1. Systolic blood pressure: \\\u003C120 or ≥160 mm Hg or diastolic blood pressure ≥110 mm Hg\n2. Arm circumference \\>52 cm (or the upper limit of the validated BP device)\n\nD. Medical History Exclusions:\n\n1. Self-reported weight loss or gain of 15 pounds during prior 2 months\n2. Active cardiovascular disease or any event in the prior 6 months, including coronary artery bypass grafting (CABG), percutaneous transluminal coronary angioplasty (PTCA), myocardial infarction (MI), cerebrovascular accident (CVA), or congestive heart failure (CHF) exacerbation requiring hospital admission\n3. Cancer diagnosis or treatment in the last 2 years (non-melanoma skin cancer or localized breast or prostate or bladder cancer not requiring systemic therapy is acceptable)\n4. Gastrointestinal surgery or history that affects nutrition absorption or requires a specific diet that will deter DASH diet adherence\n5. Pregnancy or lactation or planned pregnancy during the study period\n6. Any emergency department (ED) visit for asthma or chronic obstructive pulmonary disease (COPD) in the last 6 months\n7. Hypoglycemia hospitalization in the last 12 months\n8. Any other serious illness or condition not compatible with participation as determined by the investigators\n\nE. Lifestyle and Other Exclusions:\n\n1. Significant food allergies, preferences, intolerances, or dietary requirements that would interfere with diet adherence\n2. Consumption of more than 14 alcoholic drinks per week or consumption of more than 6 drinks on one or more occasion per week\n3. Active substance use disorder that would interfere with participation\n4. Extreme food insecurity\n5. Participation in or planning to start weight loss program\n6. Current participation in another clinical trial that could interfere with the study protocol\n7. Anticipated change in residence outside of eligible states prior to the end of the study\n8. Families with more than 6 adults at dinner time (children count as half an adult)\n\nF. Investigator discretion",{"count":295,"type":20},150,[23],"GoFreshSE is a randomized control trial, testing the effects of a home-delivered, dietitian-assisted, DASH-patterned grocery intervention on blood pressure in adults with high blood pressure in Florida, Georgia, and Tennessee.",[26,299,165,300],"Elevated Blood Pressure","Dietary Intervention",[26,302,303,304,305,306,307],"Dash Diet","Low Sodium","Diet","Nutrition","Clinical trial","Dietitian",{"date":143,"type":35},{"date":310,"type":35},"2025-10-14",{"date":119,"type":20},{"name":313,"class":42},"Beth Israel Deaconess Medical Center",{"id":315,"slug":316,"hasResults":12,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":83,"sex":16,"minAge":51,"maxAge":322,"enrollmentInfo":323,"targetDuration":4,"studyType":21,"phases":325,"briefSummary":326,"conditions":327,"keywords":331,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":334,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":43},"100582854","ketone-ester-and-salt-keas-in-older-adults-100582854","NCT06868719","Ketone Ester And Salt (KEAS) in Older Adults","Ketone Supplementation as a Strategy to Reduce the Negative Health Effects of High Dietary Salt in Older Adults","KEAS-O","Inclusion Criteria:\n\n* Between the ages of 60-85\n* Resting blood pressure no higher than 150\u002F90\n* BMI below 35 kg\u002Fm2 (or otherwise healthy)\n* Free of any metabolic disease (diabetes or renal), pulmonary disorders (COPD, severe asthma, or cystic fibrosis), cardiovascular disease (peripheral vascular, cardiac, or cerebrovascular)\n* Do not have any precluding medical conditions that prevent participants from exercising (i.e., cardiovascular issues, or muscle\u002Fjoint issues including painful arthritis) or giving blood (e.g., blood thinners)\n\nExclusion Criteria:\n\n* High blood pressure - greater than150\u002F90 mmHg\n* Obesity (BMI \\> 30 kg\u002Fm2)\n* History of metabolic disease (diabetes or renal disease), pulmonary disorders (e.g., COPD, severe asthma, \\& cystic fibrosis), and cardiovascular disease (peripheral vascular, cardiac, or cerebrovascular).\n* Medical issues that prevent safe exercise (i.e., cardiovascular issues, or muscle\u002Fjoint issues including painful arthritis)\n* Medical issues that prevent giving blood (e.g., blood thinners).\n* Current smoking, using smokeless tobacco, or vaping (within past 12 months)\n* Current pregnancy","85 Years",{"count":324,"type":20},35,[23],"Most Americans consume excess dietary salt based on the recommendations set by the American Heart Association and Dietary Guidelines for Americans. High dietary salt impairs blood pressure control by affecting systemic blood vessels and the kidneys. These changes contribute to excess salt consumption being associated with increased risk for chronic kidney disease and cardiovascular disease, the leading cause of death in America. Salt is particularly deleterious in older adults who are more likely to exhibit salt-sensitive hypertension. However, salt consumption remains high in the United States. Thus, there is a critical need for strategies to counteract the effects of high dietary salt as consumption is likely not going to decrease. One promising option is ketones, metabolites that are produced in the liver during prolonged exercise and very low-calorie diets. While exercise and low-calorie diets are beneficial, not many people engage in these activities. Limited evidence indicates that ketone supplements improve cardiovascular health in humans. Additionally, published rodent data indicates that ketone supplements prevent high salt-induced increases in blood pressure, blood vessel dysfunction, and kidney injury. Our human pilot data also indicates that high dietary salt reduces intrinsic ketone production, but it is unclear whether ketone supplementation confers humans' protection against high salt similar to rodents. Therefore, the investigators seek to conduct a short-term high-dietary salt study to determine whether ketone supplementation prevents high dietary salt from eliciting increased blood pressure, blood vessel dysfunction, and kidney injury\u002Fimpaired blood flow. The investigators will also measure inflammatory markers in blood samples and isolate immune cells that control inflammation. Lastly, the investigators will also measure blood ketone concentration and other circulating metabolites that may be altered by high salt, which could facilitate novel therapeutic targets to combat high salt.",[328,26,329,330,189],"Salt; Excess","Aging","Inflammation",[189,332,329,330,333],"Salt","Cardiovascular Disease",{"date":143,"type":35},{"date":336,"type":35},"2025-03-06",{"date":338,"type":20},"2027-12-31",{"name":340,"class":42},"Indiana University",{"id":342,"slug":343,"hasResults":12,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":347,"eligibilityCriteria":348,"healthyVolunteers":83,"sex":16,"minAge":349,"maxAge":350,"enrollmentInfo":351,"targetDuration":4,"studyType":21,"phases":352,"briefSummary":353,"conditions":354,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":355,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":359,"locationsCount":43},"100481169","ketone-ester-and-salt-keas-in-young-adults-100481169","NCT05545501","Ketone Ester and Salt (KEAS) in Young Adults","Ketone Supplementation as a Strategy to Reduce the Negative Health Effects of High Dietary Salt in Young Adults","KEAS","Inclusion Criteria:\n\n* Between the ages of 19-39\n* Resting blood pressure no higher than 150\u002F90\n* BMI below 35 kg\u002Fm2 (or otherwise healthy)\n* Free of any metabolic disease (diabetes or renal), pulmonary disorders (COPD, severe asthma, \\& cystic fibrosis), cardiovascular disease (peripheral vascular, cardiac, or cerebrovascular)\n* Do not have any precluding medical conditions that prevent participants from exercising (i.e., cardiovascular issues, or muscle\u002Fjoint issues including painful arthritis) or giving blood (e.g., blood thinners).\n\nExclusion Criteria:\n\n* High blood pressure - greater than 150\u002F90 mmHg\n* Obesity (BMI \\> 30 kg\u002Fm2)\n* History of metabolic disease (diabetes or renal disease), pulmonary disorders (e.g., COPD, severe asthma, \\& cystic fibrosis), and cardiovascular disease (peripheral vascular, cardiac, or cerebrovascular).\n* Medical issues that prevent safe exercise (i.e., cardiovascular issues, or muscle\u002Fjoint issues including painful arthritis)\n* Medical issues that prevent giving blood (e.g., blood thinners).\n* Current smoking, using smokeless tobacco, or vaping (within past 12 months)\n* Current pregnancy","19 Years","39 Years",{"count":324,"type":20},[23],"Most Americans consume excess dietary salt based on the recommendations set by the American Heart Association and Dietary Guidelines for Americans. High dietary salt impairs the ability of systemic blood vessels and the kidneys to control blood pressure, which contributes to excess salt consumption being associated with increased risk for chronic kidney disease and cardiovascular disease, the leading cause of death in America. There is a critical need for strategies to counteract the effects of high dietary salt as consumption is likely not going to decrease. One promising option is ketones, metabolites that are produced in the liver during prolonged exercise and very low-calorie diets. While exercise and low-calorie diets are beneficial, not many people engage in these activities. However, limited evidence indicates that ketone supplements improve cardiovascular health in humans. Additionally published rodent data indicates that ketone supplements prevent high salt-induced increases in blood pressure, blood vessel dysfunction, and kidney injury. Our human pilot data also indicates that high dietary salt reduces intrinsic ketone production, but it is unclear whether ketone supplementation confers humans protection against high salt similar to rodents. Therefore, the investigators seek to conduct a short-term high dietary salt study to determine whether ketone supplementation prevents high dietary salt from eliciting increased blood pressure, blood vessel dysfunction, and kidney injury\u002Fimpaired blood flow. The investigators will also measure inflammatory markers in blood samples and isolate immune cells that control inflammation. Lastly, the investigators will also measure blood ketone concentration and other circulating metabolites that may be altered by high salt, which could allow us to determine novel therapeutic targets to combat high salt.",[328,26],{"date":143,"type":35},{"date":357,"type":35},"2023-03-24",{"date":338,"type":20},{"name":340,"class":42},{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":366,"eligibilityCriteria":367,"healthyVolunteers":12,"sex":16,"minAge":368,"maxAge":369,"enrollmentInfo":370,"targetDuration":4,"studyType":21,"phases":372,"briefSummary":373,"conditions":374,"keywords":375,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":386},"100652177","comparison-of-office-and-cuffless-ambulatory-blood-pressure-guided-management-in-patients-with-hypertension-100652177","NCT07770477","Comparison of Office and Cuffless Ambulatory Blood Pressure-Guided Management in Patients With Hypertension","Comparison of Clinical Outcomes Between Office and Cuffless Ambulatory Blood Pressure-guided Management in Patients With Hypertension","CUFFLESS","Inclusion Criteria:\n\n* 24 hour mean SBP ≥ 130 mmHg by cuffless ambulatory BP monitor\n* aged ≥30 and \\\u003C80 years\n* voluntarily decide to participate in this clinical trial and provide written informed consent after being adequately informed.\n* willing and able to comply with the requirements of the study protocol\n\nExclusion Criteria:\n\n* Did not agree with this clinical trial and did not provide informed consent\n* Office SBP ≥ 190 mmHg, or diastolic BP (DBP) \\\u003C 60 mmHg.\n* Diagnosed secondary hypertension.\n* Hospitalization for stroke, myocardial infarction (MI) or unstable angina within the last 6 months\n* Coronary revascularization (percutaneous coronary intervention \\[PCI\\] or coronary artery bypass grafting \\[CABG\\]) within the last 12 months.\n* Planned to perform coronary revascularization (PCI or CABG) in the next 12 months.\n* History of sustained atrial fibrillation (AF) or ventricular arrhythmias at entry influencing the BP measurement of ring-type cuffless BP monitoring device.\n* Severe valvular disease or valvular disease likely to require surgery or percutaneous valve replacement during the trial.\n* Underlying heart disease: Hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), rheumatic heart disease or congenital heart disease\n* Uncontrolled diabetes mellitus (serum fasting glucose \\> 200 mg\u002FdL or glycated hemoglobin \\[HbA1c\\] \\>8%).\n* Severe liver dysfunction (alanine aminotransferase \\[ALT\\] \\> 3 times the upper limit of normal (ULN) value).\n* Severe renal dysfunction (end stage renal disease \\[ESRD\\] on dialysis or estimated glomerular filtration rate \\[eGFR\\] \\\u003C30 ml\u002Fmin\u002F1.73m², or serum creatinine \\>2.5 mg\u002FdL.\n* Malignancy history within 5 years.\n* Severe cognitive impairment or mental disorders.\n* Participating in other clinical trials other than observation registry","30 Years","79 Years",{"count":371,"type":20},3000,[23],"Hypertension is a major risk factor for cardiovascular and cerebrovascular diseases, including stroke and myocardial infarction. Blood pressure (BP) fluctuates throughout the day in response to physical activity, emotional states, and sleep. However, hypertension diagnosis and management are commonly based on BP measurements obtained in the clinic or at home, which may not fully reflect these variations. This can contribute to discrepancies between office and out-of-office BP, including white-coat and masked hypertension.\n\nAmbulatory blood pressure monitoring (ABPM) provides information on BP throughout daily activities and sleep, but conventional cuff-based ABPM may be limited by discomfort, accessibility, and logistical challenges. Recently, cuffless wearable devices have enabled repeated BP monitoring without the use of a conventional inflatable cuff.\n\nThe CUFFLESS study is a multicenter, prospective, randomized controlled trial comparing two strategies for the management of hypertension: cuffless ambulatory BP-guided management and conventional office BP-guided management. Participants will be randomly assigned to either management strategy and followed for clinical outcomes. The primary objective is to determine whether hypertension management guided by cuffless ambulatory BP monitoring reduces the occurrence of cardiovascular events compared with management guided by conventional office BP measurements.",[26],[376,377],"Cuffless Blood Pressure Monitoring","Ambulatory Blood Pressure Monitoring","2026-08-17",{"date":227,"type":35},{"date":381,"type":20},"2026-08-24",{"date":383,"type":20},"2036-12-31",{"name":385,"class":42},"Seoul National University Hospital",9,{"id":388,"slug":389,"hasResults":12,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":393,"eligibilityCriteria":394,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":182,"enrollmentInfo":395,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":397,"conditions":398,"keywords":399,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":402,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":4},"100628747","a-real-world-study-of-the-effectiveness-of-angiotensin-receptor-neprilysin-inhibitor-therapy-in-hypertensive-patients-in-the-united-arab-emirates-100628747","NCT07465666","A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates","Real-world Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor (ARNi) Therapy in Lowering Blood Pressure in Hypertensive Patients in the United Arab Emirates","REAL-HTN","Inclusion criteria:\n\n1. Adult male or female patients (≥18 years).\n2. Patients with physician-diagnosed hypertension (as defined by international guidelines including the American Heart Association\u002FAmerican College of Cardiology \\[AHA\u002FACC\\] guidelines and\u002For the 2024 European Society of Cardiology \\[ESC\\] guidelines).\n3. Patients with documented office blood pressure ≥130\u002F80 mmHg prior to initiating treatment (ARNi or monotherapy) or transitioning from monotherapy to ARNi.\n4. Patients who are either antihypertensive therapy naïve or currently receiving antihypertensive monotherapy (ACE inhibitor\u002FARB\u002FCCB) with a physician-directed requirement to transition to ARNi.\n\n   Note: Patients who transition from one monotherapy to another during the study are not eligible for inclusion.\n5. Patients willing to provide written informed consent to participate in the study.\n\nExclusion criteria:\n\n1. Patients with malignant or severe hypertension (systolic blood pressure \\[SBP\\] ≥180 mmHg, diastolic blood pressure \\[DBP\\] ≥110 mmHg) at baseline.\n2. Patients with secondary causes of hypertension, as determined by the treating physician.\n3. Patients with a history of, or at risk of developing, angioedema.\n4. Patients with evidence of severe renal impairment (e.g., estimated glomerular filtration rate \\[eGFR\\] \\\u003C30 mL\u002Fmin\u002F1.73 m\\^2).\n5. Pregnant or lactating women.\n6. Patients with serum potassium level ≥5.5 mmol\u002FL at baseline.",{"count":396,"type":20},500,"The aim of this study is to evaluate the real-world effectiveness of ARNi (sacubitril\u002Fvalsartan) therapy and antihypertensive monotherapy in reducing blood pressure in hypertensive patients residing in the United Arab Emirates. Antihypertensive monotherapies will include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and calcium channel blockers (CCBs).",[26],[400,401,273],"Angiotensin Receptor-Neprilysin Inhibitor","Sacubitril\u002Fvalsartan",{"date":143,"type":35},{"date":404,"type":20},"2026-08-15",{"date":406,"type":20},"2027-08-15",{"name":408,"class":151},"Novartis Pharmaceuticals",{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":4,"eligibilityCriteria":415,"healthyVolunteers":12,"sex":16,"minAge":416,"maxAge":4,"enrollmentInfo":417,"targetDuration":4,"studyType":21,"phases":419,"briefSummary":421,"conditions":422,"keywords":423,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":425,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":430,"locationsCount":43},"100417429","phase-4-secondhand-tobacco-smoke-and-cardiovascular-disease-100417429","NCT04715568","Secondhand Tobacco Smoke and Cardiovascular Disease","Occult Cardiovascular Disease With Chronic Exposure to Secondhand Tobacco Smoke","Inclusion Criteria:\n\n* Must be able to understand and provide informed consent.\n* Adults \\>= 40 years of age.\n* Must have a history of occupational exposure to secondhand tobacco smoke for at least 5 years such as flight attendants who worked for airlines before the smoking ban on aircrafts went into effect or casino workers who worked at casinos with no smoke-free policies.\n* Must have never smoked or have a remote history of light smoking defined as follows:\n\n  * Lifetime smoking history equivalent to \\\u003C 1 pack-year and\n  * No smoking history for \\>= 20 years at the time of enrollment.\n\nExclusion Criteria:\n\n* Inability or unwillingness of a participant to give written informed consent or comply with study protocol.\n* Subject is pregnant, breast-feeding, or plans to become pregnant.\n* Current therapy with angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB).\n* Known intolerance to ACE inhibitor or ARB.\n* History of angioedema.\n* Conventional indication for ACE inhibitor or ARB (e.g., history of myocardial infarction, known cardiomyopathy).\n* Blood pressure less than 90 mm Hg systolic or 60 mm Hg diastolic while standing or sitting.\n* Known unilateral or bilateral renal artery stenosis higher than 70%.\n* Renal insufficiency (Creatinine Clearance \\\u003C30 mL\u002Fmin by Cockcroft-Gault calculation).\n* Current regular use of NSAIDs defined as daily use on 5 or more days of the week for more than one month.\n* Potassium supplementation or serum potassium level of 5.0 milliequivalents (mEq)\u002FdL or higher at V1.\n* Current use of a potassium sparing diuretic.\n* History of clinically overt cardiovascular disease including: stable or unstable angina; chest discomfort and dyspnea with baseline exertion; symptomatic coronary artery disease (as defined by history of abnormal stress test; cardiac catheterization showing \\>70% coronary artery stenosis; history of revascularization; pathologic Q waves on EKG); poorly controlled resting hypertension (SBP\\>160\u002F DBP\\>95); congestive heart failure (CHF) (as defined by left ventricular ejection fraction (LVEF) \\\u003C55%; physical exam findings of CHF; symptomatic pulmonary edema); significant (\\>mild) valvular heart disease; congenital heart disease; cardiac arrhythmias including frequent premature atrial or ventricular contractions (\\>5 per minute).\n* History of clinically overt pulmonary disease that may interfere with study procedures, including: greater than mild asthma, COPD, emphysema, chronic interstitial lung disease, and pulmonary hypertension.\n* Neuromuscular disorders or physical disability to perform exercise testing using an ergometer.\n* Significant history of recreational drug use other than marijuana as defined by: recreational drug use within the last 30 years of recruitment (or) recreational drug use at a frequency of more than once a month before 30 years.\n* Marijuana use more than once a week.\n* Other uncontrolled chronic illnesses which in the judgment of the study physician would interfere with completing study procedures.\n* Failure to keep screening appointments or other indicators of non-adherence.\n* Concomitant participation in another interventional study.\n* Subjects with BMI \\\u003C15 or \\>40 kg\u002Fm2.\n* MRI Scan Participation Exclusion Criteria - The participants will be excluded from the MRI portion of the study if they have a metallic object embedded or implanted in their body that is incompatible with Magnetic Resonance (MR) scanning, including MR incompatible pacemaker or defibrillator.","40 Years",{"count":418,"type":20},100,[420],"PHASE4","This is a double-blind randomized placebo-controlled crossover clinical trial of efficacy and safety of an FDA-approved angiotensin receptor blocker (losartan) to improve cardiopulmonary outcomes in individuals with pre-Chronic Obstructive Pulmonary Disease (COPD) due to prolonged exposure to secondhand tobacco smoke.",[165,26],[424],"Second Hand Tobacco Smoke",{"date":143,"type":35},{"date":427,"type":35},"2021-03-30",{"date":429,"type":20},"2026-12-31",{"name":431,"class":42},"University of California, San Francisco",{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":438,"eligibilityCriteria":439,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":440,"targetDuration":441,"studyType":88,"phases":4,"briefSummary":442,"conditions":443,"keywords":446,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":453,"completionDateStruct":454,"leadSponsor":456,"locationsCount":43},"100652894","refocus-htn-us-west-a-data-infrastructure-to-characterize-individuals-with-hypertension-100652894","NCT07780500","REFOCUS-HTN US-WEST: A Data Infrastructure to Characterize Individuals With Hypertension","REFOCUS-HTN US-WEST: a Data Infrastructure to Characterize Contemporary Individuals With Hypertension, Their Care, Health Outcomes, and Wellbeing","REFOCUS-HTN","Inclusion Criteria:\n\nThe SCALED Cohort will be identified from the REFOCUS-HTN Cohort which includes men and women ≥ 18 years of age with established hypertension in the KPNC EHR from January 2012 through March 31, 2029. Established hypertension will be defined as one of the following:\n\n* ≥1 outpatient, non-emergency department diagnosis of hypertension;\n* ≥2 consecutive outpatient measures of systolic blood pressure ≥130 mmHg at least 90 days apart;\n* ≥2 consecutive outpatient measures of diastolic blood pressure ≥80 mmHg at least 90 days apart.\n\nAdditional Eligibility Criteria for SCALED:\n\n* Hypertension diagnosis within the past 18 months prior to screening.\n* At least 6 months of continuous health plan coverage prior to initial visit.\n\nExclusion Criteria:\n\n* Diagnosed cause of secondary hypertension from drug or alcohol induced, or renovascular hypertension;\n* Bariatric surgery or GLP1 prescription in the last 12 months;\n* Exposure to an aldosterone synthase inhibitor or a mineralocorticoid receptor antagonist in the last 12 weeks;\n* Last known estimated glomerular filtration rate \\\u003C 45 mL\u002Fmin\u002F1.73m2 (according to the CKD-EPI equation) at the time of screening;\n* Kidney transplant;\n* Currently receiving dialysis;\n* Current enrollment in any cardiovascular or blood pressure interventional trial.",{"count":396,"type":20},"6 Months","The goal of the REFOCUS-HTN US-WEST program is to gain a better understanding of the role of a hormone called aldosterone in the development of hypertension. The SCALED sub-study is an observational cohort study that will enroll from REFOCUS-HTN cohort for prospective data collection.",[26,444,445],"Aldosterone Disorder","Cardiovascular Disease (CVD)",[26,447,448,449,450],"Aldosterone","aldosterone dysregulation","aldosterone disorder","cardiovascular disease (CVD)","2026-08-14",{"date":34,"type":35},{"date":32,"type":20},{"date":455,"type":20},"2029-03",{"name":457,"class":42},"Kaiser Permanente",{"id":459,"slug":460,"hasResults":12,"nctId":461,"briefTitle":462,"officialTitle":463,"acronym":464,"eligibilityCriteria":465,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":322,"enrollmentInfo":466,"targetDuration":4,"studyType":21,"phases":468,"briefSummary":469,"conditions":470,"keywords":472,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":479,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":484,"locationsCount":486},"100652679","emergency-department-initiated-team-based-care-for-severe-hypertension-100652679","NCT07777237","Emergency Department-Initiated Team-Based Care for Severe Hypertension","Emergency Department-Initiated, Team-Based Care to Reduce Severely Elevated Blood Pressure","EDIT-SBP","Inclusion Criteria:\n\n1. Age 18 through 85 years.\n2. Two or more emergency department blood pressure measurements with systolic blood pressure \\>=180 mm Hg or diastolic blood pressure \\>=110 mm Hg.\n3. History of episodic hypertension management, defined as evidence that hypertension care has been intermittent, fragmented, or primarily reactive rather than supported by stable longitudinal outpatient management. This includes one or more of the following: recurrent ED or urgent care visits for elevated blood pressure or blood-pressure-related concerns; no established primary care clinician or usual source of care; no documented outpatient hypertension follow-up; no recent antihypertensive medication initiation, adjustment, or titration despite persistently elevated blood pressure; or, for a person without a formal hypertension diagnosis, at least two prior healthcare encounters with blood pressure \\>160\u002F90 mm Hg.\n4. Verbal fluency in English.\n5. The treating clinician expects discharge rather than inpatient admission and does not identify hypertensive emergency syndrome, acute target-organ injury requiring inpatient care, or another condition requiring admission or alternative immediate management.\n\nExclusion Criteria:\n\n1. Hypertensive emergency syndrome, acute target-organ injury requiring inpatient care, an acute cardiovascular, neurologic, or renal condition requiring immediate inpatient or procedural management, or any other need for hospital admission.\n2. Unable to verbalize comprehension of the study or complete the teach-back consent process.\n3. Pregnant or planning to become pregnant during the next year.\n4. Severe blood pressure elevation suspected by the treating clinician to be primarily due to uncontrolled pain or anxiety; the person may be reassessed after symptom control.\n5. Standardized research blood pressure below 140\u002F90 mm Hg.\n6. Stage 3B chronic kidney disease or estimated glomerular filtration rate below 45 mL\u002Fmin\u002F1.73 m2.\n7. Severe blood pressure elevation thought to be due to secondary hypertension, medication effect, or drug or stimulant use requiring a different management pathway.\n8. Excessive alcohol use, defined as 21 or more drinks per week for men or 14 or more drinks per week for women.\n9. Systolic heart failure with known left ventricular ejection fraction below 40%.\n10. Prior transplant of any type.\n11. Major psychiatric disorder, dementia, or another condition that in the investigator's judgment would make participation unsafe or impractical.\n12. Inability or unwillingness to perform home blood pressure monitoring according to protocol.\n13. Currently prescribed four or more antihypertensive medications.\n14. Any other condition that, in the investigator's judgment, would compromise participant safety, informed consent, or data integrity.",{"count":467,"type":20},700,[23],"EDIT-SBP is a pragmatic, randomized clinical trial evaluating whether an emergency department (ED)-initiated team-based care program improves blood pressure control among adults discharged from the ED after severe hypertension without hypertensive emergency. Participants will be assigned 1:1 to team-based care or usual care. Team-based care includes guideline-based antihypertensive prescribing during the ED visit or within 24 hours after discharge, a cellular home blood pressure monitor, structured remote monitoring, virtual clinical pharmacist medication management through 6 months, and community health worker\u002Fpatient navigator support. Usual care consists of standard ED discharge care and outpatient follow-up at the treating clinician's discretion. The primary outcome is mean systolic blood pressure measured in person at 6 months by blinded outcome assessors. Participants will be followed for 12 months for blood pressure, emergency care use, cardiovascular events, safety, quality of life, healthcare utilization, and economic outcomes.",[471,26],"Severe Hypertension",[473,474,475,476,477,478,471],"Emergency Department","Team-Based Care","Remote Patient Monitoring","Clinical Pharmacist","Community Health Worker","Blood Pressure Control",{"date":32,"type":35},{"date":481,"type":20},"2026-10-30",{"date":483,"type":20},"2031-06-30",{"name":485,"class":42},"Henry Ford Health System",4,{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":493,"eligibilityCriteria":494,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":322,"enrollmentInfo":495,"targetDuration":4,"studyType":21,"phases":497,"briefSummary":498,"conditions":499,"keywords":505,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":510,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":515,"locationsCount":517},"100609422","a-randomized-placebo-procedure-controlled-trial-of-the-enhancor-system-pulmonary-artery-denervation-to-evaluate-safety-and-efficacy-in-patients-with-combined-pre--and-post-capillary-pulmonary-hypertension-associated-with-left-heart-disease-100609422","NCT07214376","A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease","A Randomized Placebo-procedure Controlled Trial of the Multi-Pole Pulmonary Artery Radiofrequency Ablation Enhancor System PULmonary Artery Denervation Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease","The PULSE-LHD","Inclusion Criteria:\n\n1. Subject is ≥18 and ≤85 years of age\n2. Subject is diagnosed with chronic HF due to left-sided heart disease for at least 6 months prior to screening (regardless of LVEF), and remains symptomatic despite maximally tolerated class I GDMT for left heart failure and CRT as appropriate per US or EU guidelines according to region of enrollment\n3. Subject is clinically stable, defined as:\n\n   * No hospitalizations for heart failure for at least 1 month; no major changes in societal guideline-recommended class I oral GDMT for left heart failure for at least 1 month; no CRT or ICD implant in the prior 3 months; and no anticipated major changes in any HF-GDMT (other than possibly diuretic dose) or planned cardiac rhythm management device implantation after the procedure\n   * SBP is ≥90 and ≤160 mmHg and resting HR is ≥50 and ≤100 bpm (≤110 bpm for atrial fibrillation)\n4. PASP (RVSP) is ≥30 mmHg on the baseline TTE.\n5. Subject has New York Heart Association (NYHA) class II, III or IVa symptoms (IVa is defined as symptoms with minimal exertion or at rest, but the patient is able to ambulate and does not require continuous intravenous medications).\n6. Subject has 6MWD at baseline ranging from 100 to 450 m limited by dyspnea or fatigue and not orthopedic or other non-HF-related issues\n7. Subject has NT-proBNP ≥600 pg\u002FmL for patients with LVEF ≤40% or ≥200 pg\u002FmL for patients with LVEF \\>40% at the time of screening (a central lab will be made available for sites that cannot measure NT-proBNP)\n8. Subject is able and willing to follow all aspects of the research protocol including medication compliance and follow-up visits and testing.\n9. Subject or the subject's legally designated representative signs an IRB\u002FEC approved informed consent form prior to study participation.\n\nExclusion Criteria:\n\n1. Subject has a life expectancy of less than 1 year due to non-cardiovascular causes.\n2. Subject has known hypertrophic cardiomyopathy with either left ventricular (LV) outflow tract obstruction or systolic anterior motion (SAM) of the anterior leaflet of the mitral valve; pericardial disease; or infiltrative or active inflammatory myocardial disease, including known amyloidosis\n3. Subject has severe stenosis or regurgitation of any heart valve, moderate or severe stenosis of the aortic valve, or any degree of stenosis of the pulmonic valve\n4. Subject has symptomatic carotid stenosis, or transient ischemic attack (TIA) or stroke in the prior 30 days or any prior stroke with a permanent residual deficit with modified Rankin Scale (mRS) score ≥4\n5. Subject has any prior intracranial hemorrhage with or without a residual deficit, or any known intracranial pathology pre-disposing to bleeding (e.g. mass, AV fistula, aneurysm, etc.)\n6. Subjects with a known bleeding diathesis or who will refuse blood transfusions\n7. Subjects allergic to heparin (including heparin induced thrombocytopenia), unless bivalirudin or argatroban can be used for procedural anticoagulation\n8. Subjects with life threatening allergy to contrast dye that cannot be adequately pre-medicated, or any prior contrast-related anaphylaxis\n9. Subject has congenital heart disease other than mitral valve prolapse or a PFO\n10. Subject had coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) in the prior 6 months or is anticipated to undergo CABG or PCI within 12 months after randomization.\n11. Subject has any pacemaker with an intracardiac sensing or pacing lead or wire implanted in the prior 3 months, or CardioMEMS HF System or other intracardiac pressure monitoring system, or cardiac contractility modulation system or baroreceptor activation therapy implanted within the prior 3 months, or any plans to implant any of these devices within 12 months after the procedure.\n12. Subject has undergone atrial fibrillation ablation within the prior 6 months or is anticipated to undergo atrial fibrillation ablation within 12 months after randomization.\n13. Subject has undergone heart valve surgery or transcatheter valve intervention within the prior 6 months or is anticipated to undergo heart valve surgery or transcatheter valve intervention (e.g., valve repair or replacement, valvuloplasty) within 12 months after randomization.\n14. Subject has any tricuspid or pulmonic valve implants (implanted annuloplasty rings are allowed).\n15. Subject has an inferior vena cava (IVC) filter implant.\n16. Subject has received a prior heart or heart-lung transplantation or is listed for heart or heart-lung transplantation or is anticipated to receive a ventricular assist device (VAD) implant within 6 months after randomization.\n17. Subjects with intracardiac thrombus on TTE.\n18. Subjects with pericardial effusion ≥10 mm on TTE\n19. Subject's PH is predominantly due to WHO Group 1, 3, 4, or 5. Note: Multifactorial features of PH may be present, but the predominant diagnosis must be WHO Group 2 CpcPH.\n20. Subject has been treated with any group 1 PAH-targeted drugs, including sotatercept, within the prior month or is planned to receive such therapy after randomization.\n21. Subject is anticipated to undergo any surgery within 6 months after randomization (other than minor surgeries requiring only local anesthesia).\n22. Subject has severe renal insufficiency (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m2 by the CKD-EPI formula, or on dialysis).\n23. Subject has severe liver insufficiency (Child-Pugh classification C).\n24. Subject has platelet count \\\u003C100 × 109\u002FL.\n25. Subject has systemic inflammatory or other disease requiring long-term use of oral glucocorticoids or immunosuppressants.\n26. Subject has active infection requiring oral or intravenous antibiotics.\n27. Subject has a body mass index (BMI) \\>45 kg\u002Fm².\n28. Subjects with severe respiratory disease, defined as any disorder of the respiratory system with diffusing capacity of the lungs for carbon monoxide (DLCO) \\\u003C40% AND total lung capacity (TLC) \\\u003C60% AND forced expiratory volume in one second (FEV1) \\\u003C70% by plethysmography; OR who require ambulatory or long-term oxygen therapy\n29. Subject has known severe untreated sleep apnea. Note: Subjects with sleep apnea treated with CPAP\u002FBiPAP for at least the prior 3 months are not excluded.\n30. Subjects with pulmonary embolism or deep vein thrombosis in the prior 6 months.\n31. Subject is a pregnant or breastfeeding woman, or a woman planning to become pregnant within one year. Women of child-bearing potential must have a negative pregnancy test within 1 week of randomization.\n32. Subject is participating in another clinical trial of an investigational drug or device that has not reached its primary endpoint.\n33. Subject has severe cachexia\u002Ffrailty, substance abuse, or any other condition that the investigator believes may affect the subject's ability to comply with or complete all the study requirements including follow-up visits.\n34. Subject is a member of a vulnerable population who, in the judgment of the investigator, is unable to give Informed Consent for reasons of incapacity, immaturity, adverse personal circumstances or lack of autonomy. This may include individuals with mental disability, children, impoverished persons, persons in prisons, persons in emergency situations, homeless persons, nomads, refugees, and those incapable of giving informed consent. Vulnerable populations may also include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces, and persons kept in detention.",{"count":496,"type":20},750,[23],"The goal of this clinical study is to evaluate the safety and efficacy of percutaneous pulmonary artery denervation with the Multi-Pole Pulmonary Artery Radiofrequency Ablation Enhancor System in patients with combined pre- and post-capillary pulmonary hypertension (CpcPH) associated with left heart disease (LHD). This randomized control trial will compare the investigational device (The Enhancor System) to control (medical therapy.)\n\nParticipants who will consist of patients with chronic heart failure (HF) who are receiving maximally tolerated guideline-directed medical therapy (GDMT) for left heart failure, are clinically stable, and who have been diagnosed with CpcPH by right heart catheterization (RHC), will be treated with PADN and followed for 3 years.",[500,501,26,502,165,99,503,504],"Pulmonary Hypertension","Heart Failure With Reduced Ejection Fraction","Vascular Diseases","Heart Failure With Preserved Ejection Fraction","Heart Failure With Mid Range Ejection Fraction",[506,507,99,508,509],"Pulmonary Artery Denervation","Pulmonary Hypertension Due to Left Heart Disease","pulmonary hypertension","left heart failure",{"date":227,"type":35},{"date":512,"type":20},"2026-07-30",{"date":514,"type":20},"2031-12-31",{"name":516,"class":151},"Pulnovo Medical, Inc.",6,{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":522,"acronym":4,"eligibilityCriteria":523,"healthyVolunteers":83,"sex":16,"minAge":17,"maxAge":524,"enrollmentInfo":525,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":527,"conditions":528,"keywords":531,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":535,"startDateStruct":536,"completionDateStruct":4,"leadSponsor":538,"locationsCount":43},"100054784","diabetes-and-heart-disease-risk-in-blacks-100054784","NCT00001853","Diabetes and Heart Disease Risk in Blacks","* IINCLUSION AND EXCLUSION CRITERIA\n\nCRITERIA FOR INCLUSION:\n\nEthnicity: Black\n\nThis is a study of adult African Americans and Blacks that were born in Africa but are now living in the United States. As African American people are multi-ethnic, we will in this initial investigation, study two different groups of African American. To enroll participants must self-identify as African Americans and be born in the United States, with American born parents or be born in Africa with African born parents. In both groups we will study sex differences in the role of obesity and TG levels on cardiovascular disease. In the future, we plan to expand the study to include other groups which self-identify as African Americans (i.e.AfroCarribeans and Hispanic blacks).\n\nOnly blacks are included in this study because the focus of this study is on gender differences in blacks in risk factors for CAD, specifically obesity, TG levels and TG related CAD risk factors. Unlike Caucasian women, premenopausal black women do not appear to be as protected from heart disease as a result of their gender. One model to study this apparent decrease in gender\n\nrelated cardioprotection in black women is to compare black men to black women. An alternative model would be to compare black women to Caucasian women. However, since the primary focus of this work is on gender differences rather than racial differences comparing black women to men is a superior model. Other racial groups do not share the loss of gender-related cardioprotection found in blacks, and have been excluded. Further the advantage of comparing black men and women is that this comparison provides a better control of dietary, cultural and genetic factors.\n\nAge: The age range of the participants will be between 18 and 70 years. As stated in the original protocol on page 14: Future investigations are planned which will involve similar comparisons between premenopausal and postmenopausal black women and between whites and blacks. To investigate risk for glucose intolerance, diabetes and cardiovascular risk factors, it is no longer sufficient to maintain the age range between 18 and 50 years. We need to expand to an age range with an increased prevalence of these risk factors.\n\nMedical History: To participate in the study subjects should identify themselves as healthy. This is important so the broadest possible sample of people will enroll. The fact that people are healthy will be confirmed by the history, physical and laboratory tests done as part of the screening visit. People with established coronary artery as evidenced by history of myocardial infarction, coronary artery bypass surgery or PTCA will be allowed to participate if they are not currently having angina.\n\nCRITERIA FOR EXCLUSION:\n\nBlack Ethnicity other than American or African.\n\nAs stated in the inclusion criteria black people are a multi-ethnic group. In this initial investigation we are focusing on African Americans who are American born and Africans living in the United States who are African born. In the future, we will expand the study to include other groups of blacks such as individuals of Afro-Caribbean and Hispanic blacks.\n\nMedications: People who take medications that are known to alter the parameters which are under investigation in this study will be excluded. People taking medications to treat hyperlipidemia will be included but analyses will be adjusted to take this into account. Subjects on thyroid hormone replacement will be included if their TSH is normal.\n\nDiabetes: Because diabetes affects insulin sensitivity and TG levels all people with diabetes even if the diabetes is controlled with diet alone will not be enrolled in the study.\n\nPregnant or Breastfeeding: Women who are pregnant, breastfeeding, or have an infant that is less than four months of age will be excluded. This is because the physiologic changes associated with pregnancy, breastfeeding or recent childbirth affect the parameters under study.\n\nMenstrual History: Now that postmenopausal women are included, menstrual history will be taken but women with irregular menses and hysterectomy will not be excluded. Women between the ages of 40 and 55 years will have FSH checked for proper characterization. Women 56 years of age and older will be assumed to be postmenopausal. However, women on any type of injectable hormonal contraception will be excluded because hormonal contraception affects both TG levels and glucose metabolism.","70 Years",{"count":526,"type":20},2000,"It is unknown if obesity contributes to the development of heart disease in African American men and women.\n\nThis study was created to determine whether there is a relationship between sex and body size and the incidence of heart disease in African American men and women. Researchers will attempt to associate obesity with the presence of heart disease risk factors. Risk factors that will be studied include; total body fat, body fat distribution, fat content of the blood (triglyceride concentration, low density lipoproteins \\[LDL\\], and high density lipoproteins \\[HDL\\]), how fast fat is removed from the blood, and how well insulin works in the body.\n\nScientific studies have shown that obesity and increased levels of fat content in the blood are important risk factors for heart disease in Caucasian women. However, similar studies in African American women have failed to show the same correlation. In fact, it appears that African American women in all three body weight groupings, nonobese, overweight, and obese experience high death rates due to heart disease. In addition, prior research has shown that obese African American men tend to have elevated levels of fat in the blood while African American women have normal blood fat levels. Therefore, if high levels of triglycerides (fat found in the blood) are not seen in non-diabetic obese African American women, it cannot be considered a risk factor in this population. This suggests that studies conducted on Caucasian women may not provide insight into heart disease risk factors in African American women.\n\nThe study will take 2000 healthy non-diabetic African American men and women (ages 18-70) and body mass index 3 subgroups; nonobese, overweight and obese. Diabetes undeniably increases the risk of heart disease. Therefore patients suffering from diabetes will not be included in the study. Candidates for the study will undergo a series of tests and examinations over 2 outpatient visits. Subjects will have body fat analyses, resting energy expenditure measurements, an EKG (electrocardiogram), and specific blood tests.\n\nResearchers believe this study will provide significant insight into the causes of obesity and heart disease in African Americans.",[165,529,530,26],"Diabetes","Obesity",[532,533,529,333,534],"Healthy Volunteers","Health Disparities","Natural History",{"date":378,"type":35},{"date":537,"type":35},"1998-10-21",{"name":539,"class":200},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":544,"acronym":545,"eligibilityCriteria":546,"healthyVolunteers":83,"sex":16,"minAge":547,"maxAge":548,"enrollmentInfo":549,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":551,"conditions":552,"keywords":554,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":566,"locationsCount":43},"100651916","arterial-stiffness-in-children-and-young-people-with-hypertension-and-chronic-kidney-disease-100651916","NCT07768865","Arterial Stiffness in Children and Young People With Hypertension and Chronic Kidney Disease","ART-KIDS","Inclusion criteria:\n\nFor CKD participants:\n\n* Aged 10-25 years at study entry.\n* Diagnosis of CKD confirmed on at least two GFR assessments 3-months apart; eGFR will be estimated using routine bedside formulae (modified Schwartz). Participants may include those on dialysis or those with a functioning kidney transplant.\n* Able to tolerate study investigations including 24-hour ABPM, echocardiogram, vascular assessments and MRI.\n\nFor controls:\n\n* Aged 10-25 years at study entry\n* Having completed study measurements as part of other research being completed by the research group and having consented to their anonymised data being used in future research within the same research theme.\n\nExclusion criteria (for all participants):\n\n* Heart abnormalities or pre-existing cardiac disease including congenital heart disease, previous cardiac surgery or heart failure.\n* Cardiac dysrhythmia.\n* Inability to tolerate the required study investigations (out of office BP monitoring, applanation tonometry, cardiac MRI).","10 Years","25 Years",{"count":550,"type":20},200,"Age related stiffening and hardening of the arteries is often a slow process, but some conditions such as chronic kidney disease (CKD), seem to increase the rate at which the arteries stiffen even during childhood. High blood pressure (BP) is well known to lead to arterial stiffening and is often seen in children and young people (CYP) with CKD.\n\nA greater risk of arterial stiffening has been reported in children CYP with CKD compared to healthy CYP and this is thought to be related to the development of high BP, heart problems, and the worsening of kidney damage. The cause is unknown and is unlikely due to age related changes in the arterial wall seen in older adults. Potential mechanisms contributing to arterial stiffening in CYP with CKD include i) abnormalities in the interaction between the heart and the aorta (the large artery pumping blood away from the heart to the rest of the body), overactivity of the sympathetic nervous system (SNS), the body's \"stress response\", or iii) abnormal metabolism seen in CKD, where there are high levels of phosphate and other waste products circulating in the blood as a result of damage to the kidneys.\n\nIn this study, the investigators will use a variety of non invasive experimental methods to determine if arterial stiffening seen in CYP with CKD is due solely to increased BP, or whether the other potential factors listed above also contribute. This may help to eventually identify how to prevent or treat arterial stiffness in CYP with CKD and prevent its adverse impact on kidney and heart health in later life. The investigators will compare findings between those with CKD and an age, sex and BP matched control group. This control group will comprise CYP both with high BP (primary hypertension) and without high BP (healthy participants).",[553,26],"Chronic Kidney Disease",[555,26,556,557,558,559],"Chronic kidney disease","Arterial stiffness","Children","Pulse wave velocity","Cardiac MRI","2026-08-12",{"date":378,"type":35},{"date":563,"type":35},"2026-06-16",{"date":565,"type":20},"2028-06-16",{"name":567,"class":42},"King's College London",{"id":569,"slug":570,"hasResults":12,"nctId":571,"briefTitle":572,"officialTitle":573,"acronym":4,"eligibilityCriteria":574,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":575,"enrollmentInfo":576,"targetDuration":4,"studyType":21,"phases":578,"briefSummary":580,"conditions":581,"keywords":582,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":588,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":593,"locationsCount":594},"100635496","phase-2-a-study-to-evaluate-aln-agt01-rvr-in-adult-patients-with-mild-to-moderate-hypertension-pretreated-with-zilebesiran-100635496","NCT07553442","A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran","A Phase 2, Randomized, Double-blind, Placebo-controlled, Single Dose Study of the Efficacy, Pharmacodynamics, and Safety of ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran","Part A: Inclusion Criteria\n\n* Is an adult participant with a mean seated office systolic blood pressure (SBP) of at least 130 mmHg and no more than than 170 mmHg\n* Either not taking antihypertensive medication or on stable therapy with up to 2 antihypertensive medications\n\nPart B: Inclusion Criteria\n\n* Is an adult participant with a mean seated office SBP of at least 140 mmHg and no more than 170 mmHg\n* Has discontinued all prior antihypertensive medication other than a calcium channel blocker (CCB) and\u002For thiazide\u002Fthiazide-like diuretic (if taking) for at least 3 weeks\n\nBoth Parts: Exclusion Criteria\n\n* Has known secondary hypertension or serum potassium more than 5 mmol\u002FL\n* Has an estimated glomerular filtration rate (eGFR) less than 30 mL\u002Fmin\u002F1.73m\\^2\n\nNote: other protocol defined inclusion \u002F exclusion criteria apply","75 Years",{"count":577,"type":20},93,[579],"PHASE2","The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.",[26],[583,584,585,586,587],"RNAi therapeutic","oligonucleotide","Reversir","Zilebesiran","ALN-AGT01",{"date":451,"type":35},{"date":590,"type":35},"2026-04-27",{"date":592,"type":20},"2028-10-01",{"name":285,"class":151},3,{"id":596,"slug":597,"hasResults":12,"nctId":598,"briefTitle":599,"officialTitle":600,"acronym":4,"eligibilityCriteria":601,"healthyVolunteers":83,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":602,"targetDuration":4,"studyType":21,"phases":604,"briefSummary":605,"conditions":606,"keywords":607,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":612,"lastUpdatePostDateStruct":613,"startDateStruct":614,"completionDateStruct":616,"leadSponsor":617,"locationsCount":43},"100650496","nurse-led-motivational-interviewing-for-blood-pressure-control-100650496","NCT07747025","Nurse-Led Motivational Interviewing for Blood Pressure Control","The Effect of Nurse-Led Individual and Family-Involved Motivational Interviewing on Blood Pressure Control in Patients With Hypertension: A Three-Arm Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 18 years or older\n* Diagnosed with hypertension for at least 6 months\n* Using antihypertensive medication\n* Able to read and understand Turkish\n* Conscious and able to communicate\n* Providing written informed consent\n* Having at least one family member who can support hypertension management and participate in sessions when needed\n\nExclusion Criteria:\n\n* Advanced cognitive impairment\n* Active psychiatric crisis\n* History of a serious cardiovascular event within the last 3 months\n* Terminal illness\n* Serious physical condition that may prevent regular participation in intervention sessions\n* Concurrent participation in another structured education program",{"count":603,"type":20},180,[23],"Hypertension is one of the most important risk factors for cardiovascular morbidity and mortality. Effective hypertension management requires medication adherence, lifestyle modification, regular blood pressure monitoring, and self-management behaviors. Motivational interviewing is a counseling approach that may support behavior change and improve hypertension management.\n\nThis study aims to evaluate the effects of nurse-led individual motivational interviewing and family-involved motivational interviewing on blood pressure control in patients with hypertension. The study will be conducted as a single-center, three-arm, parallel-group, randomized controlled trial. A total of 180 patients with hypertension will be randomly assigned to one of three groups: usual care, individual motivational interviewing, or family-involved motivational interviewing.\n\nParticipants in the intervention groups will receive a 6-week nurse-led motivational interviewing program. In the family-involved motivational interviewing group, a family member who supports hypertension management will also participate in the sessions. Data will be collected at baseline, 6 weeks, and 18 weeks. The primary outcome is systolic blood pressure. Secondary outcomes include diastolic blood pressure, hypertension knowledge level, treatment adherence, and hypertension self-efficacy.",[26],[26,608,609,610,611],"Blood pressure control","Motivational interviewing","Family involvement","Nursing intervention","2026-08-11",{"date":560,"type":35},{"date":615,"type":35},"2026-08-01",{"date":429,"type":20},{"name":618,"class":42},"Kutahya Health Sciences University",{"id":620,"slug":621,"hasResults":12,"nctId":622,"briefTitle":623,"officialTitle":624,"acronym":625,"eligibilityCriteria":626,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":627,"enrollmentInfo":628,"targetDuration":4,"studyType":21,"phases":630,"briefSummary":631,"conditions":632,"keywords":634,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":612,"lastUpdatePostDateStruct":644,"startDateStruct":645,"completionDateStruct":647,"leadSponsor":648,"locationsCount":594},"100611282","a-novel-digital-tool-physicians-can-use-to-prescribe-exercise-to-patients-with-cardiovascular-disease-risk-factors-100611282","NCT07238556","A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors","Feasibility and Acceptability of a Novel Algorithm for Physicians to Prescribe Personalized Exercise Prescriptions to Patients With Cardiovascular Disease Risk Factors: Study Protocol for an Exploratory Randomized Controlled Crossover Trial","P3-EX","Physician Inclusion Criteria\n\n1. Practicing medical doctors employed at the study recruitment sites\n2. Do not recommend written exercise programs or plans to their patients, nor refer them to exercise clinics or exercise professionals\n3. Are willing to recruit two of their patients to deliver Prioritize Personalize Prescribe EXercise (P3-EX) and American College of Sports Medicine Physical Activity Vital Sign (ACSM PAVS)\n\nPatient Inclusion Criteria\n\n1. Sedentary: have not performed planned, structured physical activity at moderate intensity for ≥30 minutes on ≥3 days per week in the last 3 months\n2. Adults: ≥18 and ≤64 yrs\n3. ≥1 cardiovascular disease risk factors: Having obesity, hypertension, dyslipidemia, and\u002For diabetes (or prediabetes)\n\n   * Obesity: BMI ≥30 kg\u002Fm2 or WC \\>102 cm (40 in) for men and \\>88 cm (35 in) for women\n   * Hypertension: Systolic BP ≥130 mm Hg and\u002For diastolic BP ≥80 mm Hg, or on antihypertensive medication\n   * Dyslipidemia: LDL-C ≥130 mg\u002FdL (3.37 mmol\u002FL), or HDL-C \\\u003C40 mg\u002FdL (1.04 mmol\u002FL) in men and \\\u003C50 mg\u002FdL (1.3 mmol\u002FL) in women, or non-HDL-C ≥160 mg\u002FdL (4.14 mmol\u002FL), or on lipid-lowering medication, or TC ≥200 mg\u002FdL (5.18 mmol\u002FL)\n   * Diabetes (or prediabetes): FBG ≥100 mg\u002FdL or HbA1c ≥5.7%, or on medication for diabetes\n4. Healthy: Having no signs or symptoms of or have cardiovascular or renal disease, or other diseases or health conditions that significantly limit physical activity engagement\n5. Not pregnant or lactating\n6. Not a cigarette smoker or quit smoking ≥6 months ago\n7. Consume \\\u003C2 alcoholic drinks daily\n8. Able to use a computer or phone with internet access\n9. Fluent in English\n10. Willing to maintain their medication routine and habitual diet and not follow other exercise or nutrition programs.\n\nPatient Exclusion Criteria 4a. Have pain or discomfort in the chest, neck, jaw, or arms; dizziness or syncope; shortness of breath at rest or with mild exertion; unusual fatigue or shortness of breath with usual activities; orthopnea; ankle edema; intermittent claudication; palpitations; or known heart murmur 4b. Stroke or cancer survivors or currently have cancer, chronic obstructive pulmonary disease, musculoskeletal injury, chronic back pain, depression, dementia, or other diseases or health conditions that are deemed to significantly limit physical activity engagement.","64 Years",{"count":629,"type":20},72,[23],"The investigators will conduct a feasibility and pilot efficacy randomized controlled trial to test the usability and user satisfaction of an evidence-based digital health tool the investigators developed for physicians to use to Prioritize Personalize Prescribe EXercise (P3-EX) to patients with cardiovascular disease (CVD) risk factors. The investigators will recruit 24 physicians from two local hospitals in CT, USA. Physicians will recruit two patients each (N=48) having CVD risk factors. Physicians will deliver a P3-EX exercise prescription (ExRx) to one of their patients (n=24) and the American College of Sports Medicine Physical Activity Vital Sign (ACSM-PAVS) ExRx to the other (n=24) in a random sequence crossover design. Physicians and patients will rate the feasibility and acceptability of each method using validated questionnaires. Patients will perform their prescribed ExRx for 12 weeks and complete a self-report exercise diary to monitor exercise adherence with virtual oversight from University of Connecticut (UConn) Graduate Research Assistants. Before and after the exercise intervention, the investigators will measure patient CVD risk factors and physical activity (PA) levels via accelerometry. The primary aim is to evaluate the feasibility and acceptability of P3-EX for physicians to use to prescribe exercise to patients with CVD risk factors, and the secondary aim is to explore the preliminary efficacy of P3-EX to improve patient CVD risk factors, PA levels, and exercise adherence. The investigators hypothesize P3-EX will be feasible for physicians to use to prescribe customized exercise routines for patients with CVD risk factors, and physicians and patients will be satisfied with P3-EX.",[26,58,633,530,333],"Diabetes Mellitus",[635,636,637,638,639,640,641,642,643],"Exercise prescription","Exercise Therapy","Physical Activity","Preventive Health Services","Health Behavior","Medical Informatics Applications","Health technology","Precision Medicine","Primary Health Care",{"date":560,"type":35},{"date":646,"type":35},"2026-03-30",{"date":429,"type":20},{"name":649,"class":42},"University of Connecticut",{"id":651,"slug":652,"hasResults":12,"nctId":653,"briefTitle":654,"officialTitle":655,"acronym":656,"eligibilityCriteria":657,"healthyVolunteers":12,"sex":658,"minAge":17,"maxAge":4,"enrollmentInfo":659,"targetDuration":4,"studyType":21,"phases":661,"briefSummary":662,"conditions":663,"keywords":667,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":612,"lastUpdatePostDateStruct":671,"startDateStruct":672,"completionDateStruct":674,"leadSponsor":676,"locationsCount":678},"100608263","the-preeclampsia-postpartum-prevention-trial-100608263","NCT07199283","The PreEclampsia Postpartum Prevention Trial","The PEPP Trial: A Postpartum Bundle Intervention to Improve Cardiometabolic Health in Women After a First Pregnancy Affected by Preeclampsia - a Multi-centre Randomised Controlled Trial","PEPP","Inclusion Criteria\n\n* First-time mothers postpartum\n* Preeclampsia during first pregnancy\n* Age ≥ 18 years\n* Singleton live birth (infant still alive)\n* Ability to understand and speak Swedish, English\n* Having a smartphone (Android or iOS)\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Pre-pregnancy hypertension\n* Diabetes mellitus type I or II\n* Cardiovascular disease\n* Kidney disease\n* Systemic lupus erythematosus\n* Antiphospholipid syndrome\n* Previous or current eating disorders\n* Ongoing new pregnancy","FEMALE",{"count":660,"type":20},356,[23],"The goal of this clinical trial is to learn if a postpartum bundle intervention can improve cardiometabolic health and lifestyle-related factors in women who have had preeclampsia during their first pregnancy. The main questions it aims to answer are:\n\n* Does the 9-month intervention reduce systolic and diastolic blood pressure?\n* Does the intervention promote postpartum weight loss?\n* Does the intervention affect weight and blood pressure depending on early pregnancy BMI? Researchers will compare the bundle intervention to standard care to see if the intervention improves cardiometabolic health and lifestyle outcomes.\n\nAll participants will attend clinical visits for outcome assessments.\n\nParticipants in the intervention group will:\n\n* Receive online targeted screening and group meetings with study personnel\n* Use the trial-specific PEPP app to access self-monitoring tools for blood pressure and weight, lifestyle modification, and health education\n* Follow the intervention in two phases: starting after inclusion (≈8 weeks postpartum) with a Light phase (baseline-3 months) and progressing to an Intensive phase (3-9 months)",[664,665,26,165,666,530],"Preeclampsia","Postpartum Period","Overweight",[664,668,669,26,670],"Postpartum prevention","Prevention cardiometabolic disease","Postpartum weight loss",{"date":560,"type":35},{"date":673,"type":35},"2026-04-20",{"date":675,"type":20},"2028-04",{"name":677,"class":42},"Karolinska Institutet",2,{"id":680,"slug":681,"hasResults":12,"nctId":682,"briefTitle":683,"officialTitle":683,"acronym":4,"eligibilityCriteria":684,"healthyVolunteers":12,"sex":658,"minAge":416,"maxAge":685,"enrollmentInfo":686,"targetDuration":4,"studyType":21,"phases":688,"briefSummary":689,"conditions":690,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":612,"lastUpdatePostDateStruct":692,"startDateStruct":694,"completionDateStruct":696,"leadSponsor":698,"locationsCount":43},"100579627","melatonin-effects-on-cardiovascular-disease-mechanisms-in-midlife-women-a-randomized-clinical-trial-100579627","NCT06826755","Melatonin Effects on Cardiovascular Disease Mechanisms in Midlife Women: A Randomized Clinical Trial","Inclusion Criteria\n\n* Age 40-55 years old\n* Female individuals with intact uterus and at least one ovary\n* Hypertension\n\n  o Defined as a prior diagnosis of hypertension, use of antihypertensive agents, or office SBP\u002FDBP ≥130\u002F80 mmHg\n* On stable medical regimen (≥ 2 months) if taking other medications\n\nExclusion Criteria\n\n* Prescription sleeping medications or melatonin supplementation\n* Pregnant or lactating\n* Use of tobacco, nicotine or vaping products\n* Night shift work\n* On prescription aspirin\n* Severe lactose intolerance\n* History of substance use disorder\n* History of suicidal ideation\n* History of clinically diagnosed anemia (within the past 5 years) or low hemoglobin levels (\\\u003C11.6 g\u002FdL) within the past 12 months\n* Active cancer\n* Severe daytime sleepiness (score \\>15 at the Epworth Sleepiness Scale \\[ESS\\])81\n* Current or recent (within the past 2 months) participation in other research studies at the discretion of study investigators\n* Inability to provide written consent and\u002For to speak and read English\n* Any other medical, geographic, or social factor making study participation impractical","55 Years",{"count":687,"type":20},70,[23],"The purpose of this research is to study the effects of 12 weeks of melatonin supplementation compared to placebo in women who are in the menopause transition (perimenopause) and have high blood pressure.",[691,26],"Perimenopause",{"date":693,"type":35},"2026-08-13",{"date":695,"type":35},"2025-05-23",{"date":697,"type":20},"2028-01",{"name":699,"class":42},"Mayo Clinic"]